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Study Objective. To determine whether recommendations made by pharma-
cists and accepted by hospital physicians resulted in fewer postdischarge
readmissions and urgent care visits compared with recommendations that
were not implemented.
Design. Prospective substudy of pharmacist recommendations.
Setting. Tertiary care academic medical center and private community-based
physician practices and community pharmacies.
Patients.A total of 192 patients aged 18 years or older who were a subsam-
ple of a randomized, prospective study, who were admitted with a previ-
ous diagnosis of one of nine cardiovascular or pulmonary diseases or
diabetes mellitus or had received oral anticoagulation therapy and who
were discharged to community-based care provided by private physicians
and community pharmacists.
Measurements and Main Results. Pharmacy case managers performed evalua-
tions for patients and made recommendations to inpatient physicians.
Patients received drug therapy counseling, a drug therapy list, and a wallet
card at discharge. Data were collected from patients and private physicians
for 90 days after discharge. Pharmacy case managers made 546 recom-
mendations to inpatient physicians for 187 patients (97%). Overall, 260
(48%) of the 546 recommendations were accepted. The acceptance rate
was lower for patients who had an urgent care visit compared with the
other patients (33.6% vs 52.2%, p=0.033). High acceptance rates were
noted for updating the record after medication reconciliation (36 patients
[78%]) and when there was an actual allergy (2 [100%] of 2 patients) or
medication error (2 [100%] of 2 patients). Physicians were less likely to
accept recommendations related to drug indications (p<0.001), drug effi-
cacy (p=0.041), and therapeutic drug and disease state monitoring
(p=0.011). Recommendations made for patients with a relatively greater
number of drugs were also less likely to be accepted (p=0.003).
Conclusion. Recommendations to reconcile medications or address actual
drug allergies or medication errors were frequently accepted. However,
only 48% of all recommendations were accepted by inpatient physicians,
and there was no impact on health care use 90 days after discharge. This
study suggests that recommendations by pharmacy case managers were
underused, and the low acceptance rate may have reduced the potential to
avoid readmissions.
Key Words: hospital readmissions, adverse drug reactions, pharmacy ser-
vices.
(Pharmacotherapy 2013;33(1):11–21)
Hospital readmissions are a major clinical
and economic problem in the United States.1, 2
One in five elderly patients are readmitted
within 30 days of discharge, and one in three
are readmitted within 90 days, costing Medi-
care $17.4 billion in 2004.1 A similar study
found that almost 1 in 10 nonelderly patients
with Medicaid were readmitted within 1 month
after discharge in 2007.3 Another study found
that 16% of hospital admissions were due to
adverse drug reactions (ADRs).4 The provision
of more extensive pharmacy services, such as
admission histories, drug protocol management,
and ADR management, has been shown to sig-
nificantly reduce hospital readmissions and
mortality.5–8
Inpatient staff physicians, now more fre-
quently known as hospitalists and specialists, are
constrained by limited time and are often unable
to optimize therapy for every medical issue
before patient discharge. Acute medical prob-
lems take priority, and once the issue is
resolved, the patient is discharged back to the
community. The prospective payment model,
focused primarily on the admission issue, may
leave some chronic medical problems
unaddressed by hospitalists. As a result, some
patients may be transitioned to outpatient care
without full consideration of all chronic condi-
tions.9 Hospital payment models and insufficient
care coordination are recognized as contributors
to high readmission rates.1, 9–11 New policies
outlined in the Patient Protection and Affordable
Care Act provide incentives for health care
practitioners to create new care models in their
institutions that improve outcomes and
minimize costly readmissions.1
The Joint Commission, the National Quality
Forum, and the Centers for Medicare and Med-
icaid Services have launched quality improve-
ment initiatives promoting the development of
multidisciplinary care models focused on reduc-
ing readmissions.5 The proposed model of
inpatient care, supported by numerous studies,
is a multidisciplinary team working together to
optimize patient outcomes.2, 5, 12–15 This team
includes physicians, pharmacists, social workers,
nurses, physical therapists, and others to
optimize the inpatient stay and facilitate transi-
tions of care. A 2006 systematic review summa-
rizing the outcomes of 36 studies involving
pharmacist-provided care to hospital inpatients
showed a positive impact on a number of pro-
cess and outcome measures.2 However, of the
six studies that included hospital readmission,
pharmacists had a direct impact in only one.
Other studies have demonstrated that specific
pharmacist-provided services reduce health care
use after discharge.16–18 When pharmacists work
with the inpatient team, studies have found that
pharmacists’ recommendations resulted in
positive clinical and economic outcomes, with
acceptance rates of drug therapy recommenda-
tions as high as 95%.12, 19–22
Although including pharmacists on inpatient
teams is now common, their role in reducing
readmissions remains unclear.23, 24 The Iowa
Continuity of Care (ICOC) study is a randomized
trial designed to determine whether specialized
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pharmacy case managers (PCMs) can reduce
adverse drug events (ADEs), readmissions, and
urgent care visits.25 Patients were enrolled and
participated in the trial through June 2012.
Because the study requires that medical records
be obtained from private physicians, followed
by an extensive evaluation of case abstracts and
adjudication of events, overall results will not
be available until late 2013. During the process
of providing data to the external Data and
Safety Monitoring Board, it was revealed that
there was no apparent effect of the pharmacy
intervention at the first planned interim analy-
sis. It was also found that less than half of the
PCM recommendations were being accepted by
inpatient physicians. The PCMs had been
informing investigators that it was not uncom-
mon for inpatient physicians to express that
they did not want to change long-term therapy
because patients were being cared for by pri-
mary care physicians elsewhere. These findings
led us to explore the types of recommendations
that were accepted and whether acceptance
reduced readmissions and urgent care visits.
The investigators thought that these findings
deserved more rapid dissemination, rather than
waiting until the entire study results are
known.
Hospital readmissions, in part, are due to
behaviors by patients and private physicians that
cannot be controlled by inpatient physicians.
Because hospitals will increasingly be at risk for
costs of readmissions, the preliminary findings
of the ICOC trial suggest that more potent
strategies are needed during both the hospital-
ization and postdischarge periods. Thus, the
objective of this substudy of the ICOC trial was
to compare readmission rates, emergency
department use, and urgent care visits for
patients who had recommendations made by the
PCMs that were accepted or declined by
inpatient physicians.
Methods
This study was conducted at the University of
Iowa Hospitals and Clinics (Iowa City, IA), a
large, tertiary care, academic medical center.
The background and methods of the parent
study, the ICOC trial, have been published pre-
viously.25 Our substudy included patients in one
of the intervention groups of the parent study
who received recommendations by the PCMs.
The study was approved by the University
of Iowa Institutional Review Board for Human
Subjects, and all patients provided signed
informed consent.
The primary purpose of the ICOC study was
to improve communication between the tertiary
health center inpatient care (inpatient physicians
and PCMs) and community-based care (commu-
nity physicians and pharmacists), with a goal of
reducing readmissions and urgent care visits.
For that reason, a more population-based
approach was used; the PCMs were located
centrally outside the hospital services, and they
covered many key inpatient services. However, a
second purpose of the ICOC study was to
reduce ADRs both during hospitalization and
after discharge. Therefore, the PCM identified
drug-related problems during the inpatient stay
and communicated recommendations to the
inpatient physicians. Only one or two PCMs
participated in the study at any given time. Four
PCMs participated over the course of the present
substudy; all were Doctor of Pharmacy (Pharm.D.)
graduates who had completed at least 1 year of
postgraduate pharmacy residency training
accredited by the American Society of Health-
System Pharmacists.
After the patients had provided signed
informed consent, data were collected by a
research assistant. The PCMs were then informed
of whether the patient was randomized into an
intervention group. The PCMs performed com-
prehensive medication reconciliations and identi-
fied drug-related problems within 24 hours of
admission by collecting information from
patients, caregivers, the electronic medical record,
and community pharmacy records. The PCMs
met with patients every 2 or 3 days (Monday
through Friday) throughout the admission to pro-
vide education on drug indications, goals of ther-
apy, ADEs, drug adherence mechanisms, and self-
monitoring measures. These patient education
meetings occurred regardless of whether the PCM
recommendations were accepted by the physician.
A comprehensive assessment of the current phar-
macotherapy regimen was prepared, and recom-
mendations were made to inpatient physicians to
promote compliance with current clinical practice
guidelines and best practices. The PCM recom-
mendations were documented in the electronic
medical record and were communicated to inpa-
tient physicians by telephone. Recommendations
were also communicated typically within
24 hours of admission or the identification of a
new drug-related problem. We did not capture
the number of cases that required more time to
reach the physician. These cases, however, were
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not common, and the PCMs usually spoke with
the physician within 24 hours. The PCMs
recorded all drug therapy, recommendations to
physicians, and care plans within the study elec-
tronic database. The PCMs also classified each
recommendation by type (Appendix 1) and prob-
lem category (Appendix 2) using a modification
of a validated taxonomy.26 The PCMs could cate-
gorize each recommendation into more than one
type or problem category, so the number of these
classifications exceeded the overall number of
individual recommendations. Research assistants
verified whether recommendations were accepted
or rejected using documentation in the electronic
medical record; they then assigned each recom-
mendation to the most appropriate subcategory
(Appendix 2). Recommendations that physicians
agreed with, but failed to implement, were con-
sidered to be rejected.
The PCM provided discharge education, a drug
therapy list, and a wallet card detailing each
drug’s name, indication, dosage, and directions at
discharge. If a patient was discharged on a week-
end and it was planned, the pharmacist provided
discharge education and counseling on Friday. If
the discharge plans were not clear on Friday, and
the discharge occurred over the weekend, the
pharmacist provided the discharge education by
telephone and mailed the paperwork to the
patient. The PCM work space was located offsite;
therefore, they did not participate in medical
rounds. They did, however, communicate with
the decentralized pharmacists on the various ser-
vices for serious events, which were rare. At the
time these data were collected, there were two
decentralized pharmacists who covered the nine
medical services involved in this study. There was
one decentralized pharmacist who rounded with
four internal medicine teams and one family med-
icine team and one pharmacist who covered three
cardiology teams. Decentralized pharmacists did
not round with the orthopedics service.
Eligible patients were required to speak English
or Spanish, to be 18 years of age or older, and to
have a previous diagnosis of hypertension, hyper-
lipidemia, heart failure, coronary artery disease,
myocardial infarction, stroke, transient ischemic
attack, asthma, chronic obstructive pulmonary
disease, or diabetes mellitus or had received oral
anticoagulation therapy. Eligible patients were
admitted to one of four hospital services: general
internal medicine, family medicine, cardiology,
or orthopedics. Eligible patients also had to
receive primary care from a private physician in
the community and fill their prescriptions at a
local pharmacy. Patients were excluded if they
received primary care at a medical office that
shares electronic information within the hospital
network; had prescriptions consistently filled at
the hospital-affiliated outpatient pharmacies;
could not be reached by telephone; had a life
expectancy of less than 6 months (as docu-
mented in the medical record or plans for hos-
pice); were admitted to psychiatric, surgery, or
hematology-oncology services; or had dementia,
cognitive impairment, or severe psychiatric or
psychosocial conditions (including substance
abuse). The surgery and hematology-oncology
services were excluded because these conditions
are often complicated and take precedent over
chronic medical conditions.
A research nurse made postdischarge
telephone calls to patients at 30 and 90 days to
collect self-reported data on ADRs, readmissions,
emergency department use, and urgent care
visits. All events were validated with the respec-
tive facilities by requesting medical records from
other hospitals and community physicians for all
patients after the 90-day period, including
primary care visits, hospitalizations, consultant
visits, laboratory values, and procedures. The
primary end point was combined readmissions,
emergency department use, urgent care visits, or
death within 90 days of discharge. This outcome
was compared between patients with accepted
and those with declined PCM recommendations.
Recommendation acceptance rates were strati-
fied by patient outcomes, recommendation type,
and pharmacotherapy problem category. The
Fisher exact test was used to test whether recom-
mendation acceptance rates varied by patient
outcomes, recommendation type, and pharmaco-
therapy problem. Associations between recommen-
dation acceptance rates and numeric variables
(number of drugs at admission and number of
diagnosed conditions) were assessed using logistic
regression. All hypothesis tests were performed
with 2-sided tests, and statistical significance was
accepted with a p value of less than 0.05.
Results
Of 192 patients enrolled, 187 (97%) had 546
recommendations made to the inpatient physi-
cians. The number of recommendations/patient
ranged from 1–13, with a mean ± SD of 2.9 ±
2.3. Specifically, 33.2% had one, 24.6% had two,
15.5% had three, 8.0% had four, 3.7% had five,
4.8% had six, and 10.2% had 7–13 recomm-
endations. The number of recommendations and
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the percent accepted (in parentheses) for the
four hospital services were as follows: 188
(42.6%) for orthopedics, 174 (52.3%) for inter-
nal medicine, 164 (48.2%) for cardiology, and
20 (50.0%) for family medicine. Although the
percentage of recommendations accepted for
orthopedics was somewhat lower than that for
the other services, no significant differences
were noted between services (p=0.315, Fisher
exact test). Recommendations were made to 61
physicians, and 53 (86.9%) were either special-
ists or hospitalists. These physicians consisted of
18 hospitalists and 12 other specialists on the
four internal medicine services, 20 cardiologists
on three cardiology services, three orthopedists
(one service), and eight family physicians (one
service). Thus, all of the physicians except the
family physicians were hospitalists or specialists.
Of the 546 recommendations, the most
common types were to add a drug, change drug
intensity, discontinue a drug, monitor a drug or
disease state, or schedule physician follow-up
(Table 1). Physicians accepted 260 (47.6%) of
546 recommendations. Physicians were more
likely to accept recommendations in the “other”
category (78.8%, p<0.001) but less likely to
accept recommendations related to therapeutic
drug or disease state monitoring (33.3%,
p=0.011). The recommendations in the “other”
category were typically more procedural such as
to taper a drug before discontinuation, clarify
duration, provide dietician consultation, or
restart a drug when at home.
Within 90 days of discharge, 83 patients
(44.4%) used health care resources or died
(Table 2). Specifically, 43 (23.0%) were readmit-
ted to a hospital, 46 (24.6%) were evaluated in
an emergency department, and 28 (15%) visited
urgent care. Because there could be multiple
recommendations/patient, we calculated a rec-
ommendation acceptance rate for each patient.
The acceptance rate was lower for those who
had an urgent care visit compared with all other
patients (33.6% vs 52.2%, p=0.033). No signifi-
cant association was noted between recommen-
dation acceptance rates and readmission,
emergency department visit, or death.
The most common recommendations by phar-
macotherapy problem category included drug or
indication issues (n = 237 recommendations),
risk to the patient (n = 219 recommendations),
or pharmaceutical issues (n = 102 recommenda-
tions) (Table 3). Physicians were more likely to
accept recommendations for a record update
(p<0.001). Physicians were less likely to accept
recommendations regarding drug indication
(p<0.001) and efficacy (p=0.041). Recommenda-
tions were further classified into distinct phar-
macotherapy problem subcategories. Table 4
displays selected subcategories with the most
frequent recommendations made by the PCMs.
Physicians accepted less than 50% of the recom-
mendations for potential ADEs and ADRs,
Table 1. Types of Recommendations and Acceptance Rates for the 187 Patients
Category
Recommendations
Accepted
Recommendations
Declined p Value
Refer to social services 3/3 (100) 0 (0) 0.107
Othera 41/52 (78.8) 11/52 (21.2) <0.001
Encourage adherence 4/6 (66.7) 2/6 (33.3) 0.431
Discontinue drug 49/104 (47.1) 55/104 (52.9) 0.914
Change drug intensity 55/124 (44.4) 69/124 (55.6) 0.415
Provide physician follow-up with patient 19/45 (42.2) 26/45 (57.8) 0.534
Add drug 82/195 (42.1) 113/195 (57.9) 0.060
Perform therapeutic drug or disease state monitoring 24/72 (33.3) 48/72 (66.7) 0.011
Provide patient education 3/9 (33.3) 6/9 (66.7) 0.509
Totalb 260/546 (47.6) 286/546 (52.4) NA
Data are no. (%) of recommendations for each category.
aOther included recommendations to withhold drug therapy, taper drug before discontinuation, restart home dosage, clarify duration, restart
drug therapy at home, provide dietician consultation, or not specified by pharmacist
bBecause recommendations could be included in multiple categories, the numbers in each category total 610 (for the 546 individual recom-
mendations).
Table 2. Events Occurring within 90 Days of Discharge
in the 187 Patients
Event Type
No. of
Events
No. (%) of Patients with
One or More Event
Readmission 47 43 (23.0)
Emergency
department visit
54 46 (24.6)
Urgent care visit 30 28 (15.0)
Death 5 5 (2.7)
Total 136 83 (44.4)
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untreated conditions, undertreated conditions,
and monitoring for efficacy and just over half
for inappropriate or suboptimal doses.
Recommendations were significantly less
likely to be accepted for patients as the number
of admission drugs increased. Specifically, the
odds ratio (OR) of recommendation acceptance
due to higher number of admission drugs was
estimated by logistic regression to be 0.96 (95%
confidence interval [CI] 0.93–0.99, p=0.003),
meaning that for each additional admission
drug, the odds of recommendation acceptance
decreased by 4%.
Discussion
This study found a high rate of acceptance of
recommendations when the patient had an
allergy to an ordered drug (2 [100%] of 2
patients) or when there was a medication error
(2 [100%] of 2 patients). Acceptance rates were
also high for updating the record after medica-
tion reconciliation (78%) or when there was a
therapeutic duplication (80%). However, the
overall physician acceptance rate was low
(47.5%) for all the recommendations made by
PCMs. Although there are some differences in
acceptance rates between medical services, these
differences were not significant. Because the
odds of recommendation acceptance decreased
by 4% for each additional admission drug, our
findings may be related to the high degree of
complexity exhibited by many of these patients.
This information was elucidated when our
preliminary data were prepared for the Data and
Safety Monitoring Board. The findings caused us
Table 3. Pharmacotherapy Problem Categories and Acceptance Rates for the 187 Patients
Category
Recommendations
Accepted
Recommendations
Declined p Value
Record update 28/36 (77.8) 8/36 (22.2) <0.001
Othera 8/12 (66.7) 4/12 (33.3) 0.245
Pharmaceutical issue 52/102 (51.0) 50/102 (49.0) 0.510
Risk to patient 108/219 (49.3) 111/219 (50.7) 0.541
Cost 9/22 (40.9) 13/22 (59.1) 0.664
Drug or indication issue 91/237 (38.4) 146/237 (61.6) <0.001
Efficacy issue 21/60 (35.0) 39/60 (65.0) 0.041
Totalb 260 (47.6) 286 (52.4) NA
Data are no (%) of recommendations for each category.
aOther included clarify dose, verify drug, withhold drug, postpone drug, or not specified by pharmacist.
bBecause recommendations could be included in multiple categories, the numbers in each category total 688 (for the 546 individual recom-
mendations).
Table 4. Selected Pharmacotherapy Problem Subcategories and Acceptance Rates for the 187 Patients
Category and
Subcategory
Recommendations
Accepted
Recommendations
Declined
Risk to patient
Allergy 2/2 (100) 0 (0)
Medication error 2/2 (100) 0 (0)
Monitoring for toxicity 7/10 (70.0) 3/10 (30.0)
Actual adverse drug event 8/16 (50.0) 8/16 (50.0)
Potential adverse drug event 61/136 (44.9) 75/136 (55.1)
Drug indication issue
No/unclear indication 6/10 (60.0) 4/10 (40.0)
Undertreated condition 24/56 (42.9) 32/56 (57.1)
Untreated condition 43/103 (41.7) 60/103 (58.3)
Alternative therapy 4/25 (16.0) 21/25 (84.0)
Efficacy issue
Drug adherence or administration issue 7/10 (70.0) 3/10 (30.0)
Therapeutic monitoring for effectiveness 13/42 (31.0) 29/42 (69.0)
Minimal effectiveness 2/7 (28.6) 5/7 (71.4)
Pharmaceutical issue
Inappropriate route 1/1 (100) 0 (0)
Therapeutic duplication 8/10 (80.0) 2/10 (20.0)
Inappropriate or suboptimal dose 24/44 (54.5) 20/44 (45.5)
Inappropriate or suboptimal schedule 1/3 (33.3) 2/3 (66.7)
Data are no. (%) of recommendations for each category.
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to evaluate more effective strategies to improve
care after discharge because inpatient physicians
were reluctant to make changes.
It is well established that interprofessional
teamwork requires interdependence, commit-
ment, and trust.27 One of us has extensively
evaluated physician-pharmacist collaborative
relationships and validated instruments to mea-
sure attitudes toward collaboration.28–30 We
have described the transition through five
stages of development: professional awareness
(stage 0), professional recognition (stage 1),
exploration and trial (stage 2), professional
relationship expansion (stage 3), and commit-
ment to a collaborative working relationship
(stage 4).27, 29 Although we did not measure
collaborative relationships in the present trial,
we would estimate they were at stage 1 or per-
haps stage 2, both of which are low levels of
collaboration.
The PCM recommendations included both the
acute medical problem responsible for the
admission and chronic conditions. For instance,
many patients enrolled from the orthopedics
service were often admitted for elective surger-
ies but were eligible for this study because of
their chronic conditions. The fact that PCM rec-
ommendations included medical conditions out-
side the scope of the primary reason for the
hospital admission may have contributed to the
low acceptance rate, which several inpatient
physicians mentioned anecdotally. This observa-
tion is supported by a recent study that found
hospitalists did not want to interfere with the
prescribing of the patient’s primary physician.31
These authors evaluated hospitalists, and quotes
such as the following were documented: “I don’t
cut across somebody else’s prescribing unless
I’m taking over the patient.” If the inpatient
medical team does not optimize long-term med-
ical therapy, the primary care physician may
interpret that therapeutic plan as appropriate as
determined by the tertiary care team when, in
fact, the inpatient team did not deal with those
drugs. This potential miscommunication could
lead to care gaps that then result in future read-
missions.
The rate of hospital readmissions, emer-
gency department use, and urgent care visits
within 90 days after discharge in this study
did not differ significantly between patients
whose recommendations were accepted and
those whose recommendations were declined.
One possible explanation for this finding may
be the low acceptance rate of PCM recom-
mendations. Another explanation is that many
of the recommendations that were accepted
may not have had as much influence on read-
missions compared with recommendations to
intensify therapy or to change a drug when
there is a potential ADE. A possible explana-
tion for the lower than expected acceptance
rate is that the PCMs did not round with the
teams and were not as well known to the
physicians.
Other studies investigating inpatient pharma-
cist recommendations have reported positive
clinical and economical outcomes associated
with acceptance rates of greater than
90%.12, 32, 33 Our findings are similar to those
of another study in which clinical pharmacists
performed drug therapy reviews for patients on
an internal medicine ward at a regional hospital
in Denmark (intervention group).24 Physicians
approved 39% of the 187 pharmacist recommen-
dations to modify drug therapy with no signifi-
cant difference between patients in the
intervention and control groups regarding
readmissions, emergency department use, and
visits for outpatient care 3 months after dis-
charge. In the present study, recommendations
were less likely to be accepted by physicians if
they related to drug indication (p<0.001) or effi-
cacy (p<0.041). Physicians accepted less than half
of the recommendations to address untreated and
undertreated conditions by adding or intensifying
therapy. Based on these findings, it may be that
physicians in typical inpatient settings are less
likely to accept many of the recommendations
made, especially ones that may be perceived to
be of lower importance (e.g., costs, untreated
indication, therapeutic monitoring).
Interventions to prevent ADEs have the poten-
tial to reduce health care use. It is estimated that
12–17% of patients on a general medicine ser-
vice experience an ADE after discharge, with 6–
12% resulting in emergency department visits
and 5% in hospital readmissions.23 In our study,
physicians did accept a high percentage of rec-
ommendations when there was a medication
allergy, actual ADE, or medication error. These
more serious events, however, were rare. In con-
trast, the OR of acceptance by number of drugs
was 0.96 (95% CI 0.93–0.99, p=0.003), meaning
that the odds of recommendation acceptance
decreased by 4% with each additional drug.
Patients with polypharmacy are known to be at
a higher risk of ADEs.34
Studies have shown that physicians and phar-
macists can work collaboratively to reduce ADEs
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in intensive care units. Preventable ADEs
decreased in one study by 66% (p<0.001) when
a pharmacist was added to the care team.12 In
that study, physicians accepted 362 (99%) of
366 recommendations made by the pharmacist,
which is a much higher rate than that observed
in the present study. It is possible that the
majority of recommendations in the intensive
care unit study did not focus on long-term drugs
but, rather, focused on short-term problems. In
that case, this process would increase the likeli-
hood that recommendations would be accepted
in that trial.
Improved outcomes have also been demon-
strated when adding pharmacists to medicine
teams. A 2009 Canadian study evaluated
all-cause readmission rates of 452 inpatients
randomized to usual care or enhanced care from
the addition of a clinical pharmacist to the
team.18 Patients in the clinical pharmacist arm
experienced fewer hospital readmissions at
3 months after discharge than patients in the
usual care arm (OR 0.63, 95% CI 0.42–0.94).
A recent study examined Medicare data from
11 U.S. hospitals ranking in the top or bottom
5% for mortality rates after acute myocardial
infarction.35 The role of pharmacists in high-per-
forming hospitals was described as being closely
integrated into care processes and having influ-
enced clinical decisions. In low-performing hos-
pitals, pharmacist roles were described as being
narrowly circumscribed and having limited par-
ticipation in clinical decisions. Other studies
have shown that with high acceptance rates,
pharmacist interventions can decrease costs and
improve clinical outcomes.32, 33, 36
When a patient is admitted to the hospital,
there is an opportunity to evaluate and optimize
the treatment of chronic conditions. Once the
patient is discharged, it should not be assumed
that these disease states will be appropriately
addressed. A retrospective study completed in
2007 found inpatient physicians at a large, aca-
demic teaching hospital recommended only
27.6% of discharged patients for outpatient
follow-up. More than one third of these recom-
mended follow-ups were not completed. Our
concern is that if adjustments are not made dur-
ing the inpatient stay, the primary care physician
could interpret this as approval of his or her
patient care plan by specialists at the hospital.
This could lead to many patients “falling
through the cracks,” not having the treatment of
their chronic condition optimized, and ulti-
mately resulting in a serious short-term event. It
is our opinion that these issues should be
addressed during hospitalization because they
represent missed opportunities to intervene to
improve chronic disease management.
A recent systematic review demonstrated the
positive effect pharmacists have on therapeutic,
safety, and economic outcomes in the U.S.
health system.19 Pharmacists have the ability to
impact patient outcomes in both the inpatient
and outpatient environment, as well as to facili-
tate transitions of care. Health systems that use
hospitalists or other specialists should examine
policies and procedures to improve gaps in ther-
apy when patients are discharged to the care of
primary care physicians in the community.
These gaps will be particularly important as hos-
pitals are at risk for costs associated with early
readmissions.
This study is not without limitations. This
study was purposefully designed to add PCMs
to usual pharmacy services in this hospital, in
part, because there were only two decentral-
ized pharmacists on all nine medical services.
In addition, at any given time, there was only
one or two PCMs involved with this study so
it was not possible to cover all the critical ser-
vices by PCMs. The goal of the intervention
was to provide more in-depth surveillance of
high-risk patients by specialized clinical phar-
macists located more centrally in a cardiovas-
cular risk service. Because of the broad
coverage, the PCMs did not function as part
of the inpatient medical team because this
study deployed them on the nine inpatient ser-
vices. Instead, they centrally covered these ser-
vices and made therapy recommendations
based on a comprehensive review of each
patient’s medical case. The physicians may
have been reluctant to accept recommenda-
tions from a pharmacist working outside of
the medical team without previously estab-
lished trust and rapport. However, the PCMs
were frequently in the hospital as they visited
study patients, usually every 2–3 days. Second,
data were collected by reviewing medical
records and self-reporting. Events may have
been missed if they were not documented in
the records that were reviewed or the patient
failed to report it during follow-up telephone
calls. However, this study is one of the most
comprehensive evaluations of readmissions and
ADRs because medical records from the hospi-
tal, community physicians, and community
hospitals were obtained to minimize any
missed events.
18 PHARMACOTHERAPY Volume 33, Number 1, 2013
Based on our experience with this trial to
date, we propose specific structural features of
any similar interventions. Because of the chal-
lenges and limitations for physicians in tertiary
care, recommendations for long-term therapy
should probably be made to the community
physician. This intervention will need to be
structured so that more intense recommenda-
tions and follow-through can be achieved.
It would also be helpful if the care plans come
from a PCM who is easily identified as a mem-
ber of the team of providers caring for the
patient during the inpatient stay.
Conclusion
Physicians accepted the majority of PCM rec-
ommendations to reconcile medications on
admission and for patients with actual drug
allergies or medication errors. However, the
overall acceptance rate was 48% despite the fact
that recommendations were based on clinical
guidelines and published evidence. Patients with
accepted pharmacist recommendations did not
show reduced readmissions or emergency
department or urgent care visits within 90 days
after discharge. Future studies should identify
efficient strategies to improve the long-term care
of hospitalized patients both during and after
discharge. These studies should help to clarify
the proper care structure and role of pharmacists
in hospital settings and how their involvement
can improve continuity of care with community
providers.
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Appendix 1. Types of Recommendations
Discontinue drug
Add drug
Change drug intensity
Perform therapeutic drug or disease state monitoring
Provide physician follow-up with patient
Provide community pharmacist follow-up with physician
Provide insurance follow-up
Refer to social services
Refer to home health care
Provide patient education
Encourage adherence
Othera
a
Other included recommendations to withhold drug therapy, taper
drug before discontinuation, restart home dosage, clarify duration,
restart drug therapy at home, provide dietician consultation, or not
specified by pharmacist.
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Categories and Subcategories Definitions
Risks to patient
Allergy Patient had known allergy to drug or drug class, or actual ADE or ADR.
Patient had a previous undesirable experience with the drug and therefore
either discontinued the drug or wants to discontinue the drug due to
previous experience
Potential ADE or ADR Patient is at increased risk for an ADE or ADR, including drug interaction
or absolute or relative contraindication to a drug
Medication error Errors that occur in the process of ordering or delivering a drug, regardless
of whether an injury occurred or the potential for injury was present (i.e.,
not a therapeutic decision)
Therapeutic monitoring Includes drug and disease state monitoring (e.g., laboratory results, vital
signs, symptoms) for toxicity purposes
Drug or indication issues
No or unclear indication No clear indication for the drug that the patient is taking or has been
prescribed
Untreated condition Drug should be started
Undertreated condition Dose should be increased or new drug should be added
Alternative therapy Not receiving the best or most appropriate therapy (therapeutic decision)
for the indication; requires a change to a potentially more effective therapy
Efficacy issues
No evidence of effectiveness Based on clinical assessment or patient has self-discontinued a drug based
on belief of ineffectiveness
Monitor for effectiveness Includes drug and disease state monitoring (e.g., laboratory results, vital
signs, symptoms)
Drug adherence or
administration issue
Patient not taking drug or not taking drug as prescribed; need for
adherence aids and/or education about appropriate use of drug
(continued)
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Appendix 2. (continued)
Categories and Subcategories Definitions
Pharmaceutical issues
Inappropriate or suboptimal dose Dose is too high or too low; inappropriately high dose unlikely to lead to
ADR or ADE
Inappropriate or suboptimal schedule Schedule problem without changing total daily dose
Inappropriate or suboptimal route Includes inappropriate or suboptimal drug administration instructions and
convenience issues for drug administration
Therapeutic duplication Inappropriate duplication of drugs
Cost issues
Formulary adherence Replacement of nonformulary drug with formulary alternative
Less expensive alternative Switch to a generic drug or other lower cost alternative
Record update
Admission drug therapy is different
from community records
Update drug therapy profile
Label instructions do not match how
patient was actually instructed to
take the drug
Update drug therapy profile
Prescription not on profile Add drug to the profile
ADR = adverse drug reaction; ADE = adverse drug event.
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